Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Citalopram for Agitation in Alzheimer's Disease (CitAD)
This study is ongoing, but not recruiting participants.
Study NCT00898807 Information provided by JHSPH Center for Clinical Trials
First Received on May 11, 2009. Last Updated on February 13, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer's Disease
Agitation
Additional conditions recognized in this trial
Alzheimer Disease
Psychomotor Agitation
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Dyskinesias
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurodegenerative Diseases
Neurologic Manifestations
Psychomotor Disorders
Signs and Symptoms
Tauopathies
Interventions listed in this trial
citalopram
placebo
Additional drug interventions recognized in this trial
Dexetimide
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
JHSPH Center for Clinical Trials
National Institute on Aging (NIA)
National Institute of Mental Health (NIMH)
Back to top of Main Content
